Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Response to CMF according to HER-2 overexpression

Author: Richard de Boer

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

A major aim of current research in breast cancer is more effective targeting of chemotherapy. Biological markers may provide one way of identifying patients more or less likely to respond to a particular therapy/regimen. HER-2 overexpression appears to be a potential indicator of responsiveness to doxorubicin and paclitaxel, and conversely of unresponsiveness to tamoxifen. It has been suggested that HER-2 overexpression may result in a decrease in responsiveness to cyclophosphamide, methotrexate, and fluorouracil (CMF). This study examined HER-2 overexpression and clinical benefit in the 386 node-positive breast cancer patients in the first trial of CMF versus no treatment with a 20-year follow-up. …
Literature
1.
Menard S, Valagussa P, Pilotti S, Gianni L, Biganzoli E, Boracchi P, Tomasic G, Casalini P, Marubini E, Colnaghi MI, Cascinelli N, Bonadonna G: Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumour biologic variables. J Clin Oncol . 2001, 19: 329-335.PubMed
Metadata
Title
Response to CMF according to HER-2 overexpression
Author
Richard de Boer
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68445

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Meeting report

VIII International Congress of the Metastasis Research Society

Review

Imaging biochemistry: applications to breast cancer

Paper Report

Her-2/neu and topoisomerase IIaexpression in primary and metastatic breast cancer

Paper Report

ER? expression seems important in preinvasive cancers

Paper Report

Liposome-encapsulated doxorubicin in metastatic breast cancer

Research article

Comparison of written reports of mammography, sonography and magnetic resonance mammography for preoperative evaluation of breast lesions, with special emphasis on magnetic resonance mammography
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits